NEW YORK (GenomeWeb News) – Diagnostic Hybrids this week announced that it has licensed exclusive worldwide rights from Case Western Reserve University to pharmacogenomics test technology for monitoring HIV treatment.
The Athens, Ohio-based firm licensed novel yeast-based virus cloning technology invented by Eric Arts, an associate professor of medicine in the division of infectious diseases, department of medicine, at Case Western Reserve School of Medicine. It said that the technology can monitor the success of HIV treatments by determining drug resistance and disease "strength" of the virus.
Diagnostic Hybrids and Case Western were awarded a $5 million grant last year from the Ohio Third Frontier Biomedical Research and Commercialization Program to accelerate commercial development of a suite of diagnostic products for HIV, hepatitis, and influenza using the yeast vector technology.
Financial and other terms of the license were not disclosed.